Curative effect of Dingqi analgesic patch on cancer pain: a single-blind randomized controlled trail  by Wang, Changjun et al.
TOPIC
JTCM |www. journaltcm. com April 15, 2013 |volume 33 | Issue 2 |
Online Submissions:http://www.journaltcm.com J Tradit Chin Med 2013 April 15; 33(2): 176-180
info@journaltcm.com ISSN 0255-2922
© 2013 JTCM. All rights reserved.
CLINICAL STUDY
Curative effect of Dingqi analgesic patch on cancer pain: a sin-
gle-blind randomized controlled trail
ChangjunWang,Wei Tan, Xuhui Huang, Tingting Fu, Juze Lin, Junmin Bu, GuojianWei, Yu Du
aa
Changjun Wang, Wei Tan, Xuhui Huang, Tingting Fu,
Juze Lin, Junmin Bu, Guojian Wei, Yu Du, Department of
Traditional Chinese Medicine, Guangdong General Hospital,
Guangdong Academy of Medical Sciences, Guangdong Geri-
atric Institute, Guangzhou 510080, China
Supported by the Administration of Traditional Chinese
Medicine of Guangdong Province, China (No. 2010431)
Correspondence to: Prof. Changjun Wang, Department of
Traditional Chinese Medicine, Guangdong General Hospital,
Guangdong Academy of Medical Sciences, Guangdong Geri-
atric Institute, Guangzhou 510080, China. gzwchj@126.com
Telephone: +86-20-83827812-70522
Accepted: November 15, 2012
Abstract
OBJECTIVE: To observe the curative effect of an
acupoint application with a Dingqi analgesic patch
on moderate to severe pain caused by liver cancer.
METHODS: Forty patients with moderate to severe
pain caused by liver cancer were randomly divided
into a treatment group (TG) and a control group (CG).
Patients with moderate pain were given 100 mg qd
of a sustainably released tablet of tramadol hydro-
chloride; patientswith severepainweregiven4.2mg
q3d of the fentanyl transdermal system. The ashi
points Ganshu (BL 18), Danshu (BL 19) and Qimen
(LR 14) were chosen for the acupoint application in-
tervention. CG patients were given a sham patch
and TG patients were given a Dingqi analgesic
patch. A visual analogue scale (VAS) was used be-
fore treatment and after 1, 3, 6, 9 and 12 days of
treatment. The Karnofsky score was measured be-
fore treatment and after 12 days of treatment. Any
main adverse reactions (e.g. nausea, constipation,
dizziness and headache) were recorded after 6 and
12 days of treatment. Any skin side effects (i.e. skin
irritation and allergic reactions) were recorded.
RESULTS: The VAS in TG was significantly lower
than that in CG after 3, 6, 9 and 12 days of treat-
ment (P<0.05). There was no significant difference
in the Karnofsky score before treatment and after
12 days of treatment between CG and TG. There
were also no significant differences in the main ad-
verse reactions or skin side effects after 6 and 12
days of treatment between CG and TG (P>0.05).
CONCLUSION: The Dingqi analgesic patch can en-
hance the analgesic effect of tramadol and fen-
tanyl.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
For the past decade, pain has been listed as the fifth vi-
tal sign after blood pressure, body temperature, respira-
tion and pulse.1 Cancer pain, which is one of the most
common symptoms of cancer, is caused by tumour
compression and/or invasion of related tissues and
nerves; cancer pain considerably affects the quality of
life and mental health of patients. Because uncon-
trolled severe pain is a contributor to cancer patient sui-
cide, it is urgently necessary to relieve cancer pain both
rapidly and effectively. Cancer pain in many patients
can be relieved by an analgesic ladder designed by the
World Health Organization (WHO).2 However, some
patients need to gradually increase the dosage of analge-
sics.3 The life quality of many patients is also seriously
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affected by the adverse reactions of analgesics.4
Acupoint application with a traditional Chinese herbal
paste is used to treat many diseases.5-10 The paste can
have different formulas based on the purpose of the
treatment. Acupoint application is widely used in hos-
pitals due to its practical convenience and few side ef-
fects. Based on Traditional Chinese Medicine (TCM),
in this study, we designed a Dingqi analgesic patch, i.e.
a transdermal drug delivery system, and applied it to
patients with cancer pain. The active ingredients of tra-
ditional Chinese herbs can be absorbed through the
skin. Compared to other drug administration methods,
this method avoids many adverse reactions. Its safety
and long-lasting pain-relieving effect make the Dingqi
analgesic patch especially suitable for terminal cancer
patients and patients for whom oral administration is
not available.
METHODS
Research design
This study was a single-blind randomized controlled
trial. Individuals were randomized by a computer-gen-
erated allocation list (no sealed envelopes). The pa-
tients and nursing staff did not know to which group
the patient had been allocated. This study met the stan-
dards of medical ethics and was approved by the hospi-
tal ethics committee. All the patients signed an in-
formed consent form.
Inclusion criteria
1) Patients had to be 18 to 80 years old; 2) patients
had to meet the diagnostic criteria of cancer and had to
be diagnosed by pathology and cytology;11 3) patients
had to meet the diagnostic criteria on cancer pain12 and
had to have a VAS score of 4 to 10; 4) patients who
have had no systematic analgesic therapy; and 5) pa-
tients had to have a performance Karnofsky score ≥30.
Exclusion criteria
1) Patients who had brain metastases; 2) patients with
non-cancer-related pain; 3) patients who received che-
motherapy or radiotherapy the previous month; 4) pa-
tients with allergies or a history of drug allergy; 5) pa-
tients with cutaneous involvement or skin lesions; 6)
patients who received normal analgesic therapy in the
previous 24 h or controlled-release analgesic therapy in
the previous 72 h; 7) patients with pain in more than
three body areas; 8) patients with serious diseases such
as heart failure, liver and kidney diseases, or hematopoi-
etic disorders; 9) patients with mental disorders or non-
compliant and 10) patients who participated in other
clinical interventions.
General data
Forty inpatients, who met both the inclusion and exclu-
sion criteria, were recruited from the TCM department
of the Guangdong General Hospital between May
2010 and January 2012. The patients were randomly
divided into a treatment group (TG; n=20) and a con-
trol group (CG; n=20). The general characteristics of
the two groups are shown in Table 1.
Interventions
Dingqi analgesic patch: the composition and bioactive
compounds of the Dingqi analgesic patch are shown in
Table 2. The Dingqi analgesic patch was provided by
the TCM department of the Guangdong General Hos-
pital. All the traditional Chinese herbs purchased from
Guangzhou Caizhilin Pharmaceuticals Co., Ltd. were
pulverized and passed through a No. 80 sieve. Lauro-
capram was then added to the mixture. The mixture
was made into a patch of 0.5 cm length×0.5 cm width
× 0.5 cm thickness and stored at 4℃. A fraction of the
mixture was placed on the centre of a patch (3 cm
× 3 cm). A patch of similar size and without any drug
was used as a sham patch.
Acupoint selection and application method: one to two
ashi points (pain points), on both sides of Ganshu (BL
18), Danshu (BL 19) and Qimen (LR 14), were cho-
sen for the acupoint application intervention. Before
the acupoint application intervention, hair was shaved
and skin cleaned with 75% ethanol. To each acupoint,
only one Dingqi analgesic patch was applied to TG pa-
tients and only one sham patch was applied to the CG
patients for 12 h. The patches were changed every day
for 12 days. The application followed standard acu-
point application procedures.22
Therapeutic schedule: According to the analgesic lad-
der designed by WHO, all patients with VAS scores of
4-6 were given a sustainably released tablet of 100 mg
qd of tramadol hydrochloride (Grünenthal GmbH,
Germany); patients with VAS scores of 7-10 were given
4.2 mg q3d of a fentanyl transdermal system (Xian-
Janssen Pharmaceutical Ltd., China). In the meantime,
CG patients were given the acupoint application inter-
vention with a sham patch and TG patients were given
a Dingqi analgesic patch. During the 12-day interven-
tion, a 50 mg tramadol hydrochloride injection
(Grünenthal GmbH) was administered to patients
with moderate pain and a 5 mg morphine hydrochlo-
Table 1 The general data of all groups ( xˉ ± s )
Group
TG
CG
Male
16
15
Female
4
5
Age (year)
50.8±11.4
47.9±13.1
VAS
7.0±1.1
7.2±1.1
Karnofsky score
68.4±6.8
72.0±8.5
Notes: TG: treatment group, acupoint application with Dingqi analgesic patch; CG: control group, acupoint application with sham patch.
There were no significant differences in sex, age, VAS and Karnofsky scores between treatment group and control group (P>0.05).
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ride injection (Shenyang No. 1 Pharmaceutical Co.,
Ltd., China) was administered to patients with severe
pain.
Measurements
Pain intensity was evaluated by VAS.23 A simple nu-
meric rating scale was used with 0 for no pain or no
interference, 1-3 for mild pain, 4-6 for moderate
pain, 7-9 for severe pain24 and 10 for worse pain or
interference. The VAS was used before treatment and
after 1, 3, 6, 9 and 12 days of treatment. The Karnof-
sky score was measured before treatment and after 12
days of treatment. During the intervention, main ad-
verse reactions such as nausea, constipation, dizziness
and headache were recorded after 6 and 12 days of
treatment. Any skin side effects (e.g. skin irritation
and allergic reactions) were recorded during the inter-
vention.
Statistical analyses
Data were expressed as mean±standard deviation (SD).
The statistical analyses was performed with SPSS 13.0
version (SPSS Inc, Chicago, IL, USA). VAS at different
times was analysed by repeated-measures analysis of co-
variance. Differences between the groups were deter-
mined by one-way ANOVA. The enumeration data
were analysed by χ2 test. A P-value <0.05 was consid-
ered to be significant.
RESULTS
Based on the analysis of the repeated-measures, there
was significant difference in VAS at different times be-
tween CG and TG (F=760.813, P<0.01, Table 3).
There was no significant interaction between time and
intervention (F=3.044, P>0.05, Table 3). These results
suggest that VAS declined in both CG and TG during
the research study (Table 3). The VAS in CG and TG
had the same trend (Table 3). The VAS in TG was sig-
nificantly lower than that in CG after 3, 6, 9 and 12
days of treatment (P<0.05, Table 3). There was no sig-
nificant difference in the Karnofsky score between
CG and TG before treatment and after 12 days of
treatment (P>0.05, Table 4). There was no significant
difference in the main adverse reactions (nausea, con-
stipation, dizziness and headache) or skin side effects
(skin irritation and allergic reactions) between TG
and CG after 6 and 12 days of treatment (P>0.05,
Table 5).
DISCUSSION
Unrelieved cancer pain can cause significant distress
and disability. The results of our study showed that the
Dingqi analgesic patch is an effective treatment of pain
caused by liver cancer. This study involved patients
with liver cancer and with moderate to severe pain be-
Table 2 Composition and bioactive compounds of the Dingqi analgesic patch
Composition
Dingxiang (Flos Caryophylli)
Bingpian (Borneolum
Syntheticum)
Chunwu (Radix Aconiti)
Caowu (Radix Aconiti
kusnezoffii)
Tiannanxing (Rhizoma
Arisaematis)
Baifuzi (Rhizoma Typhonii)
Huangqi (Radix Astragali)
Jixueteng (Caulis
Spatholobi)
Ruxiang (Olibanum)
Moyao (Myrrha)
Main bioactive compounds
Eugenol, β-caryophyllene, eugenyl acetate, chavicol, vanillin, α-humulen, ylangen,
methoxybenzaldehyde, benzyl alcohol, benzaldehyde and cavychole13
D-borneol, β-terpineol, α-terpineol, neryl acetate, α-isosafrole, bornyl acetate,β-elemene, cis-caryophyllene, α-caryophyllene14
Aconitin, mesaconitin, hypaconitin14
Aconitin, mesaconitin, hypaconitin15
Beta-sitosterol, total alkaloids, guanosine, γ-aminobutyric acid and dipeptides16
Tianshic acid, cinnamic acid, linoleic acid, linolenic acid, palmitic acid, β-sitostero,
amino acid, coniferin17
Calycosin, astragaloside, glucuronic acid, astragalus polysaccharides18
Formononetin, ononin, prunetin, calycosin, afromosi, iso-sativa, iso-mucromatol,
pendulone, vestito, medicagol, methyl asiatate19
α-boswellic acid, β-boswellic acid, acetyl-α-boswellic acid, incensole,
incensole-oxide, isoincensole-oxide, serratol20
α-elemene, β-elemene, γ-elemene, elemol, furanosesquiterpenoid, erlangerin21
Percentage (%)
6.47
6.47
12.93
12.93
12.93
12.93
17.24
12.93
2.59
2.59
Table 3 Changes in VAS score ( xˉ ± s , n=20)
Group
TG
CG
Before
treatment
7.01±1.07
7.17±1.07
After 1 day of
treatment
4.46±0.68
4.81±0.78
After 3 days of
treatment
3.29±0.45
3.62±0.58a
After 6 days of
treatment
2.19±0.29
2.41±0.34a
After 9 days of
treatment
1.86±0.26
2.05±0.29a
After 12 days of
treatment
1.57±0.26
1.79±0.31a
Notes: TG: treatment group, acupoint application with Dingqi analgesic patch; CG: control group, acupoint application with sham patch.
aP<0.05 when compared to treatment group.
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fore treatment (VAS>4). After a 12-day intervention,
TG group (acupoint application with Dingqi analgesic
patch) showed a statistically significant reduction in
pain severity compared to CG group (acupoint applica-
tion with sham patch). The changes in VAS suggest
that the acupoint application intervention with the
Dingqi analgesic patch can significantly enhance the
analgesic effect of tramadol and fentanyl in liver cancer
patients. The changes in Karnofsky score suggest that
the Dingqi analgesic patch has no significant effects on
the physical status of liver cancer patients.
According to TCM, cancer pain is related to 'blood sta-
sis' or 'blood deficiency'. 'Blood stasis' can obstruct the
normal flow of 'blood' and 'Qi'. 'Blood deficiency' can
make the body lack 'blood' and 'Qi'. Dingqi analgesic
patch consisting of flos caryophylli, borneolum synthe-
ticum, radix aconiti, radix aconiti kusnezoffii, rhizoma
arisaematis, rhizoma typhonii, radix astragali, caulis
spatholobi, olibanum and myrrha can promote blood
circulation, regulate Qi and relieve pain.
The results revealed that the Chinese herbs present in
the Dingqi analgesic patch, i.e. Dingxiang (Flos Caryo-
phylli),25 Bingpian (Borneolum Syntheticum),26 Chuan-
wu (Radix Aconite),27Caowu(RadixAconitiKusnezoffii),28
Tiannanxing (Rhizoma Arisaematis),29 Baifuzi (Rhizoma
Typhonii), Huangqi (Radix Astragali)30 Jixueteng (Cau-
lis Spatholobi)31 and Moyao (Myrrha)21, can be clinically
used for pain relief.
Acupoint application is widely used in clinical practice
for pain-related diseases, such as cancer pain,32-36 asth-
ma,37 chronic bronchitis,37 chronic obstructive pulmo-
nary disease,38 chronic atrophic gastritis11 and mamma-
ry gland hyperplasia39. The mechanism by which acu-
point application relieves cancer pain is by increasing
both the brain endorphin production and the pain
threshold.40
Opioid analgesics, such as tramadol and fentanyl, have
a good pain-relieving effect in moderate to severe can-
cer pain. However, patients usually experience drug de-
pendence after a long-term administration. Moreover,
drug dependence and adverse reactions (nausea, consti-
pation, dizziness and headache) of opioid analgesics of-
ten decrease the patient's quality of life. Our research
shows that the Dingqi analgesic patch and opioid anal-
gesics have a synergistic analgesic effect. We observed
no significant skin side effects during the intervention.
In future studies, we will assess whether the Dingqi an-
algesic patch can reduce the dosage of opioid analgesics
in clinical practice for moderate to severe pain caused
by liver cancer.
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